THIS INVENTION RELATES TO NOVEL FUSION PROTEINS, COMPRISING A TARGETING PROTEIN AND A PLASMINOGEN ACTIVATOR, PREFERABLY AN ANTIBODY THAT BINDS TO P-SELECTIN, OPERABLY LINKED TO THE PLASMINOGEN ACTIVATOR DSPAALPHA 1, OR ANALOGS, FRAGMENTS, DERIVATIVES, OR VARIANTS THEREOF, WHICH ARE USEFUL AS THROMBOLYTIC AGENTS. PHARMACEUTICAL COMPOSITIONS CONTAINING THESE FUSION PROTEINS, METHODS OF USING THESE FUSION PROTEINS AS THROMBOLYTIC AGENTS, AND PROCESSES FOR SYNTHESIZING THESE FUSION PROTEINS ARE ALSO DESCRIBED HEREIN.